(Q34192420)

31 July 2017

1 reference

title

Alzheimer's disease: current and future therapeutic perspectives (English)

1 reference

31 July 2017

0 references

Gauthier S

1

1 reference

31 July 2017

1 January 2001

1 reference

Progress in Neuro-Psychopharmacology & Biological Psychiatry

31 July 2017

1 reference

31 July 2017

25

1 reference

31 July 2017

1

1 reference

31 July 2017

73-89

1 reference

A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study.

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Functional impairment in instrumental activities of daily living: an early clinical sign of dementia?

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Survival in Alzheimer's disease and vascular dementias.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Mild senile dementia of the Alzheimer type: 2. Longitudinal assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Factors affecting course and survival in Alzheimer's disease. A 9-year longitudinal study.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Predicting conversion to Alzheimer disease using standardized clinical information.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Prospects for pharmacological intervention in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

New treatments in Alzheimer disease and the continued need for placebo-controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

1 reference

7 January 2021

Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part XI. Clinical milestones in patients with Alzheimer's disease followed over 3 years

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Clinical trials and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Abnormalities of neural circuitry in Alzheimer's disease: hippocampus and cortical cholinergic innervation

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

The consortium to establish a registry for Alzheimer's disease (CERAD). Part XIV: Demographic and clinical predictors of survival in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Predictors of time to institutionalization of patients with Alzheimer's disease: the CERAD experience, part XVII.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Predicting who will develop dementia in a cohort of Canadian seniors.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Is the placebo control obsolete in a world after donepezil and vitamin E?

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Comparison of rate of annual change of mental status score in four independent studies of patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

The five-five, ten-ten plan for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Clinical research designs for emerging treatments for Alzheimer disease: moving beyond placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Rate of progression and prognostic factors in Alzheimer's disease: a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Estrogen to treat Alzheimer's disease: too little, too late? So what's a woman to do?

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

A family intervention to delay nursing home placement of patients with Alzheimer disease. A randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

The Clinical Dementia Rating (CDR): current version and scoring rules

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Predictors of cognitive and functional progression in patients with probable Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Severe impairment battery. A neuropsychological test for severely demented patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Mild cognitive impairment: clinical characterization and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

A new rating scale for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

The molecular and genetic basis of AD: the end of the beginning: the 2000 Wartenberg lecture.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Assessing individual patients for cognitive benefits from acetylcholinesterase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

The pharmacological basis for metrifonate's favourable tolerability in the treatment of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Functional assessment staging (FAST) in Alzheimer's disease: reliability, validity, and ordinality.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Mild cognitive impairment: potential pharmacological treatment options

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Brain infarction and the clinical expression of Alzheimer disease. The Nun Study

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Clinical trial designs for demonstrating disease-course-altering effects in dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Severe dementia: a common condition entailing high costs at individual and societal levels.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Mechanisms of neurodegenerative disorders: Part 1: protein aggregates.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Mechanisms of neurodegenerative disorders: Part 2: control of cell death.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

Subjective burden of husbands and wives as caregivers: a longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900149-4

7 January 2021

10.1016/S0278-5846(00)00149-4

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11263760